Licensing a Compact Fusion Platform Under the Byproduct-Material Framework

Q: What does this research mean for the field?

The United States byproduct-material framework (10 CFR Part 30) provides a suitable, graded regulatory pathway for licensing compact fusion platforms whose primary source term is a bounded tritium inventory. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.SUPPORTS_CONSENSUS.

Priyanca Ford; G L Kulcinski

doi:10.5281/zenodo.22132139

August 28, 2026Open Access

Licensing a Compact Fusion Platform Under the Byproduct-Material Framework

View Full Paper

Ask AI

Bookmark

Share

Key Points

Analyze the applicability of the United States byproduct-material regulatory framework (10 CFR Part 30) for licensing compact fusion energy systems in light of recent regulatory and statutory developments.
Synthesized the regulatory implications of the 2023 Nuclear Regulatory Commission decision and the federal ADVANCE Act for fusion technology.
Evaluated the alignment of compact fusion radiological source terms with existing materials-focused and Agreement-State-administered licensing pathways.
Characterized 10 CFR Part 30 as a viable, graded regulatory route suited for fusion machines where the primary radiological hazard is a bounded inventory of tritium.
Confirmed that the byproduct-material framework provides an established administrative path capable of execution through Agreement State radiation control programs rather than fission reactor frameworks.

Implication

Regulatory analysis demonstrates the viability of byproduct-material licensing for compact fusion devices, highlighting a graded oversight path based on bounded tritium inventories.

Abstract

Licensing a compact fusion platform under the United States byproduct-material framework (10 CFR Part 30), confirmed for fusion by the 2023 NRC determination and the ADVANCE Act. The materials-oriented, Agreement-State-administrable, graded path suits a machine whose only significant source term is a bounded tritium inventory. A regulatory-strategy analysis, not legal advice or a filed application. Shorter synthesis paper.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ford et al. (2026) studied this question.

synapsesocial.com/papers/6a93f0c06c1a8fb52e79d32e https://doi.org/10.5281/zenodo.22132139

View Full Paper

Ask AI

Bookmark

Share

Licensing a Compact Fusion Platform Under the Byproduct-Material Framework

Key Points

Implication

Abstract

Discussion

Cite This Study

Licensing a Compact Fusion Platform Under the Byproduct-Material Framework

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

Keep reading

More related papers